Key features and details
- Purity: > 90% n/a
- Suitable for: Blocking
Product nameHuman Androgen Receptor (AR-V7 specific) peptide
Purity> 90 % n/a.
Our Abpromise guarantee covers the use of ab223099 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Blocking - Blocking peptide for Anti-Androgen Receptor (AR-V7 specific) antibody [EPR15656] (ab198394)
Blocking peptide for ab198394
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at -20°C.
- Androgen receptor splice variant 3
RelevanceBelongs to the nuclear hormone receptor family. Contains nuclear receptor DNA-binding domain. Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. This target is a splice variant of Androgen receptor (UniProt P10275) lacking the C-terminal androgen binding site.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab223099 has not yet been referenced specifically in any publications.